644 related articles for article (PubMed ID: 29317800)
21. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
Kumari S; Kumar A; Samant M; Singh N; Dube A
Curr Drug Targets; 2008 Nov; 9(11):938-47. PubMed ID: 18991606
[TBL] [Abstract][Full Text] [Related]
22. Leishmaniasis.
Herwaldt BL
Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
[TBL] [Abstract][Full Text] [Related]
23. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
[TBL] [Abstract][Full Text] [Related]
24. Overview of dendritic cell-based vaccine development for leishmaniasis.
Bagirova M; Allahverdiyev AM; Abamor ES; Ullah I; Cosar G; Aydogdu M; Senturk H; Ergenoglu B
Parasite Immunol; 2016 Nov; 38(11):651-662. PubMed ID: 27591404
[TBL] [Abstract][Full Text] [Related]
25. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
26. Recent updates and perspectives on leishmaniasis.
Savoia D
J Infect Dev Ctries; 2015 Jul; 9(6):588-96. PubMed ID: 26142667
[TBL] [Abstract][Full Text] [Related]
27. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
28. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
29. Leishmaniasis: prevention, parasite detection and treatment.
Kobets T; Grekov I; Lipoldova M
Curr Med Chem; 2012; 19(10):1443-74. PubMed ID: 22360481
[TBL] [Abstract][Full Text] [Related]
30. Second-generation vaccines against leishmaniasis.
Coler RN; Reed SG
Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
[TBL] [Abstract][Full Text] [Related]
31. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
32. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
34. Recent developments in leishmaniasis vaccine delivery systems.
Bhowmick S; Ali N
Expert Opin Drug Deliv; 2008 Jul; 5(7):789-803. PubMed ID: 18590463
[TBL] [Abstract][Full Text] [Related]
35. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
Lakshmi BS; Wang R; Madhubala R
Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
[TBL] [Abstract][Full Text] [Related]
36. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
37. Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research.
Elmahallawy EK; Alkhaldi AAM; Saleh AA
Biomed Pharmacother; 2021 Jul; 139():111671. PubMed ID: 33957562
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic vaccines for leishmaniasis.
Khamesipour A
Expert Opin Biol Ther; 2014 Nov; 14(11):1641-9. PubMed ID: 25077737
[TBL] [Abstract][Full Text] [Related]
39. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous leishmaniasis: progress towards a vaccine.
Launois P; Tacchini-Cottier F; Kieny MP
Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
